0PNT Acacia Pharma Group Plc

 
TIDMACPH 
 
 
   THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION - THIS ANNOUNCEMENT 
CONTAINS INSIDE INFORMATION 
 
   Acacia Pharma Appoints Debra Hussain as Chief Commercial Officer 
 
   Cambridge, UK and Indianapolis, US -- 19 May 2021, 07:00 CEST: Acacia 
Pharma Group plc ("Acacia Pharma" or the "Company") (EURONEXT: ACPH), a 
commercial-stage biopharmaceutical company focused on developing and 
commercializing novel products to improve the care of patients 
undergoing serious medical treatments such as surgery, invasive 
procedures, or chemotherapy, announces the appointment of Debra (Deb) 
Hussain as Chief Commercial Officer. 
 
   "We continue to achieve very strong early commercial success as we 
execute the launch strategy for BARHEMSYS(R) and BYFAVO(TM) in the US 
and are delighted to welcome Deb to our high-performing team," said Mike 
Bolinder, Chief Executive Officer at Acacia Pharma. "I am so very 
pleased that we have been able to attract someone of her caliber and 
experience to join our executive team to fill the role I vacated almost 
two years ago when I assumed my current role as CEO. Deb brings 
exceptional commercial experience that we believe will complement our 
current activities, improve our organizational capabilities, and help us 
to maximize and grow the significant commercial opportunity before us, 
as we enter the next phase of accelerating our commercial growth, both 
in the US and internationally." 
 
   "I am thrilled to be joining the team at Acacia Pharma at such an 
exciting time and look forward to contributing further to the successful 
launches of BARHEMSYS and BYFAVO in the US," commented Deb Hussain. "We 
share a strong commitment to improving the lives of patients, and these 
products have the potential to positively impact millions of patients in 
the US and globally. I believe Acacia Pharma has a great future and I 
look forward to working with the team to deliver that success." 
 
   Ms. Hussain is a highly experienced commercial leader having spent over 
20 years at the global pharmaceutical company Eli Lilly and Company 
("Lilly") in a breadth of roles of increasing responsibility. These have 
included US and global product sales and marketing in both the hospital 
and out-patient settings. During her career, she has led some of the 
largest and most successful brands in the industry and has had profit 
and loss responsibility for over $2 billion of revenue. 
 
   She has consistently built and empowered high-performing teams, 
designing and implementing innovative approaches to engage customers and 
deliver best-in-class customer experiences anchored in deep insights, 
while delivering strong business results. 
 
   Recently, Ms. Hussain established and led a cross-functional team 
responsible for transforming Lilly's go-to-market model for healthcare 
professionals across 20 brands within its US Affiliate, to address the 
growing difficulty in the industry for representatives to gain physical 
access to healthcare professionals. 
 
   Prior to working in the pharmaceutical industry, Ms. Hussain practiced 
as a pediatric audiologist at Riley Hospital for Children in 
Indianapolis, Indiana after earning her Bachelor's degree at the 
University of Wisconsin-Milwaukee and her Master's degree in Audiology 
from Memphis State University. 
 
 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   Citigate Dewe Rogerson 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@citigatedewerogerson.com 
US Investors                        Media in Belgium and the Netherlands 
 LifeSci Advisors                    Chris Van Raemdonck 
 Irina Koffler                       +32 499 58 55 31 
 +1 917-734-7387                     chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
available in the US for the management of postoperative nausea & 
vomiting (PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centred in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   Acacia Pharma Group plc 
 
   The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United 
Kingdom 
 
   Company number 9759376 
 
   www.acaciapharma.com 
 
 
 
 

(END) Dow Jones Newswires

May 19, 2021 01:00 ET (05:00 GMT)

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024

Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024